{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:50:20Z","timestamp":1785757820052,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200150"],"award-info":[{"award-number":["82200150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05309-1","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:03:49Z","timestamp":1780131829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low initial hemoglobin and high-risk additional chromosomal abnormalities predict poor long-term survival in chronic phase chronic myeloid leukemia"],"prefix":"10.1007","volume":"17","author":[{"given":"Qingyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannong","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"10","key":"5309_CR1","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343\u201356.","journal-title":"Blood"},{"issue":"24","key":"5309_CR2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016;34(24):2851\u20137.","journal-title":"J Clin Oncol"},{"issue":"22","key":"5309_CR3","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/cncr.30864","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017;123(22):4391\u2013402.","journal-title":"Cancer"},{"issue":"4","key":"5309_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood. 1984;63(4):789\u201399.","journal-title":"Blood"},{"issue":"11","key":"5309_CR5","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"5309_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686\u201392.","journal-title":"Blood"},{"issue":"1","key":"5309_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48\u201356.","journal-title":"Leukemia"},{"issue":"4","key":"5309_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"8","key":"5309_CR9","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39(8):1797\u2013813.","journal-title":"Leukemia"},{"issue":"5","key":"5309_CR10","first-page":"353","volume":"41","author":"Chinese Society of Hematology CMA","year":"2020","unstructured":"Chinese Society of Hematology CMA. [The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(5):353\u201364.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"6","key":"5309_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"9","key":"5309_CR12","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/bmt.2009.359","volume":"45","author":"L Scrucca","year":"2010","unstructured":"Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transpl. 2010;45(9):1388\u201395.","journal-title":"Bone Marrow Transpl"},{"issue":"26","key":"5309_CR13","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118(26):6760\u20138.","journal-title":"Blood"},{"issue":"22","key":"5309_CR14","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","volume":"127","author":"W Wang","year":"2016","unstructured":"Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127(22):2742\u201350.","journal-title":"Blood"},{"issue":"8","key":"5309_CR15","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","volume":"34","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R, Voskanyan A, Lauseker M, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020;34(8):2074\u201386.","journal-title":"Leukemia"},{"issue":"14","key":"5309_CR16","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","volume":"126","author":"W Wang","year":"2015","unstructured":"Wang W, Cortes JE, Lin P, et al. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015;126(14):1699\u2013706.","journal-title":"Blood"},{"key":"5309_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-015-0128-2","volume":"8","author":"W Wang","year":"2015","unstructured":"Wang W, Tang G, Cortes JE, et al. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015;8:32.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"5309_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","volume":"5","author":"RE Clark","year":"2021","unstructured":"Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv. 2021;5(4):1102\u20139.","journal-title":"Blood Adv"},{"issue":"11","key":"5309_CR19","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.3324\/haematol.2022.282447","volume":"108","author":"CCB Kockerols","year":"2023","unstructured":"Kockerols CCB, Geelen IGP, Levin MD, et al. High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population. Haematologica. 2023;108(11):3156\u20139.","journal-title":"Haematologica"},{"issue":"12","key":"5309_CR20","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","volume":"94","author":"A Fabarius","year":"2015","unstructured":"Fabarius A, Kalmanti L, Dietz CT, et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol. 2015;94(12):2015\u201324.","journal-title":"Ann Hematol"},{"issue":"5","key":"5309_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32(5):415\u201323.","journal-title":"J Clin Oncol"},{"issue":"5","key":"5309_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354.","journal-title":"Leukemia"},{"issue":"20","key":"5309_CR23","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5309_CR24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41375-021-01387-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang XS, Gale RP, Huang XJ, Jiang Q. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Leukemia. 2022;36(2):482\u201391.","journal-title":"Leukemia"},{"issue":"18","key":"5309_CR25","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29(18):2514\u201320.","journal-title":"J Clin Oncol"},{"issue":"12","key":"5309_CR26","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1038\/s41375-020-0902-1","volume":"34","author":"G Ector","year":"2020","unstructured":"Ector G, Visser O, Westerweel PE, Janssen J, Blijlevens NMA, Dinmohamed AG. Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989\u20132017. Leukemia. 2020;34(12):3408\u201312.","journal-title":"Leukemia"},{"issue":"10","key":"5309_CR27","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1080\/03007995.2017.1356708","volume":"33","author":"PS Ko","year":"2017","unstructured":"Ko PS, Yu YB, Liu YC, et al. Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib. Curr Med Res Opin. 2017;33(10):1737\u201344.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"5309_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/16078454.2020.1765563","volume":"25","author":"Z Liu","year":"2020","unstructured":"Liu Z, Shi Y, Yan Z, et al. Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era. Hematology. 2020;25(1):181\u20135.","journal-title":"Hematology"},{"issue":"5","key":"5309_CR29","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41375-022-01527-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang XS, Gale RP, Zhang MJ, Huang XJ, Jiang Q. A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia. 2022;36(5):1336\u201342.","journal-title":"Leukemia"},{"issue":"19","key":"5309_CR30","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121(19):3818\u201324.","journal-title":"Blood"},{"issue":"6","key":"5309_CR31","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/bjh.13649","volume":"173","author":"M Breccia","year":"2016","unstructured":"Breccia M, Colafigli G, Molica M, et al. Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib. Br J Haematol. 2016;173(6):945\u20136.","journal-title":"Br J Haematol"},{"issue":"14","key":"5309_CR32","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5309_CR33","doi-asserted-by":"publisher","first-page":"e2486","DOI":"10.1097\/MD.0000000000002486","volume":"95","author":"YZ Qin","year":"2016","unstructured":"Qin YZ, Jiang Q, Jiang H, et al. Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients. Med (Baltim). 2016;95(2):e2486.","journal-title":"Med (Baltim)"},{"issue":"2","key":"5309_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/leu.2008.308","volume":"23","author":"J Dierov","year":"2009","unstructured":"Dierov J, Sanchez PV, Burke BA, et al. BCR\/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia. 2009;23(2):279\u201386.","journal-title":"Leukemia"},{"issue":"20","key":"5309_CR35","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","volume":"121","author":"E Bolton-Gillespie","year":"2013","unstructured":"Bolton-Gillespie E, Schemionek M, Klein HU, et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 2013;121(20):4175\u201383.","journal-title":"Blood"},{"issue":"7","key":"5309_CR36","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254\u201364.","journal-title":"J Clin Invest"},{"issue":"11","key":"5309_CR37","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1038\/leu.2015.96","volume":"29","author":"W Wang","year":"2015","unstructured":"Wang W, Cortes JE, Lin P, et al. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2015;29(11):2263\u20136.","journal-title":"Leukemia"},{"issue":"26","key":"5309_CR38","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1182\/bloodadvances.2017011858","volume":"1","author":"Z Gong","year":"2017","unstructured":"Gong Z, Medeiros LJ, Cortes JE, et al. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017;1(26):2541\u201352.","journal-title":"Blood Adv"},{"issue":"1","key":"5309_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ajh.24943","volume":"93","author":"A Alhuraiji","year":"2018","unstructured":"Alhuraiji A, Kantarjian H, Boddu P, et al. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018;93(1):84\u201390.","journal-title":"Am J Hematol"},{"issue":"25","key":"5309_CR40","doi-asserted-by":"publisher","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","volume":"117","author":"G Marzocchi","year":"2011","unstructured":"Marzocchi G, Castagnetti F, Luatti S, et al. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood. 2011;117(25):6793\u2013800.","journal-title":"Blood"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05309-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05309-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05309-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:37:25Z","timestamp":1785757045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05309-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5309"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05309-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the First Affiliated Hospital of Soochow University (Approval Number: 2017169). Written informed consent to participate was obtained from all participants prior to data collection and analysis.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable. No individual person\u2019s data (including images, videos, or other identifying details) are included in this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1108"}}